GGrantIndex
← Search

Prevention and Control

$28,157P30FY2008CANIH

Oregon Health & Science University, Portland OR

Investigators

Linked publications, trials & patents

Paper 39764100Paper 39763867Paper 39605535Paper 39435649Paper 39386578Paper 39375962Trial NCT07434128Trial NCT07278440Trial NCT07089940Trial NCT05705492Trial NCT04247425Trial NCT04172493Trial NCT04104139Trial NCT04061980Trial NCT04005690Trial NCT03961672Trial NCT03960177Trial NCT03699995Trial NCT03677531Trial NCT03649880Trial NCT03626285Trial NCT03613259Trial NCT03544125Trial NCT03479268Trial NCT03418025Trial NCT03406013Trial NCT03361436Trial NCT03347617Trial NCT03325166Trial NCT03280277Trial NCT03270059Trial NCT03261180Trial NCT03234309Trial NCT03135782Trial NCT03097588Trial NCT03028935Trial NCT03010358Trial NCT03009201Trial NCT02890979Trial NCT02869412Trial NCT02857218Trial NCT02779283Trial NCT02736617Trial NCT02522715Trial NCT02504359Trial NCT02503358Trial NCT02501759Trial NCT02498951Trial NCT02427841Trial NCT02359097Trial NCT02355262Trial NCT02312557Trial NCT02228265Trial NCT02100189Trial NCT02099864Trial NCT02092324Trial NCT02070705Trial NCT02050919Trial NCT01913015Trial NCT01748942Trial NCT01689987Trial NCT01649505Trial NCT01635413Trial NCT01620216Trial NCT01532687Trial NCT01498978Trial NCT01441882Trial NCT01422408Trial NCT01253642Trial NCT01031953Trial NCT01005914Trial NCT00983398Trial NCT00978562Trial NCT00900302Trial NCT00900068Trial NCT00900055Trial NCT00899795Trial NCT00899522Trial NCT00843167Trial NCT00822848Trial NCT00764517Trial NCT00722072Trial NCT00691652Trial NCT00662103Trial NCT00660543Trial NCT00659126Trial NCT00627276Trial NCT00516542Trial NCT00482274Trial NCT00425386Trial NCT00324324Trial NCT00303849Trial NCT00293475Trial NCT00253721Trial NCT00253643Trial NCT00238433Trial NCT00227682Trial NCT00103038Trial NCT00075387Patent 9279811

Abstract

The Cancer Prevention and Control Program aims to reduce cancer incidence, morbidity, and mortality by identifying controllable risk factors, special high-risk target groups, and molecular markers of risk and tumor aggressiveness. Using such knowledge, the program members seek to develop and test interventional strategies, and, by the translation of such knowledge into practice, to establish new standards of care. The current grant cycle has been a time of tremendous growth and development in this program, and its members have helped create new strengths in cancer prevention and control in Programs 1 (Cancer Biology) and 3 (Solid Tumors). A robust monthly Cancer Prevention and Control Seminar Series has enhanced collaborations internally and interprogrammatically, with a particular emphasis on aiding junior investigators and trainees. Progress has evolved from the investment of our leadership team in recruitment and development of faculty in our three focus areas: (1) survivorship and symptom management, (2) surveillance and epidemiology, and (3) underserved populations. There are now 27 members, 14 full and 13 associate, in this program from 14 different departments and institutes of the University. During the past grant cycle, the cancer focus of program investigators has been enhanced by the recruitment of highly-focused investigators and by terminating memberships of members whose cancer focus was deemed insufficient. The members of this group have $10.2 million in grant funding within 49 projects including $3.2 million in NCI funding (16 projects). This productive group has published 123 manuscripts in scientific literature in the past five years. Investigators are increasingly conducting intervention studies, and program investigators are helping establish the standard of care in a number of high priority areas.

View original record on NIH RePORTER →